Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus

Gastroenterology

Volumn 141, Issue 6, 2011, Pages 2000-2008

  Kastelein, Florine ^a   Spaander, Manon C W ^a   Biermann, Katharina ^a   Steyerberg, Ewout W ^a   Kuipers, Ernst J ^a   Bruno, Marco J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer Risk; Chemoprevention; Gastroesophageal Reflux Disease; Tumor

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ATORVASTATIN; CARBASALATE CALCIUM; CELECOXIB; DEXIBRUFEN; DEXKETOPROFEN; DICLOFENAC; ETORICOXIB; FLUINDOSTATIN; FLURBIPROFEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INDOMETACIN; KETOPROFEN; LANSOPRAZOLE; MELOXICAM; MEVINOLIN; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PHENYLBUTAZONE; PIROXICAM; PRAVASTATIN; ROFECOXIB; SIMVASTATIN; SULINDAC; TOLMETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG POTENTIATION; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MULTICENTER STUDY; NETHERLANDS; PRIORITY JOURNAL;

EID: 81855167480     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.08.036     Document Type: Article

References (27)

1. R.C. Haggitt Barrett's esophagus, dysplasia, and adenocarcinoma Hum Pathol 25 1994 982 993 (Pubitemid 24313642)
2. X. Fan, and N. Snyder Prevalence of Barrett's esophagus in patients with or without GERD symptoms: role of race, age, and gender Dig Dis Sci 54 2009 572 577
3. M. van Blankenstein, C.W. Looman, and B.J. Johnston Age and sex distribution of the prevalence of Barrett's esophagus found in a primary referral endoscopy center Am J Gastroenterol 100 2005 568 576 (Pubitemid 40487554)
4. J. Ronkainen, P. Aro, and T. Storskrubb Prevalence of Barrett's esophagus in the general population: an endoscopic study Gastroenterology 129 2005 1825 1831 (Pubitemid 41772961)
5. B. Avidan, A. Sonnenberg, and T.G. Schnell Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma Am J Gastroenterol 97 2002 1930 1936
6. M. Sikkema, P.J. de Jonge, and E.W. Steyerberg Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis Clin Gastroenterol Hepatol 8 2010 235 244 quiz e32
7. M. Hage, P.D. Siersema, and H. van Dekken Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean follow-up of 12.7 years Scand J Gastroenterol 39 2004 1175 1179 (Pubitemid 39656830)
8. R.C. Fitzgerald, and G. Triadafilopoulos Recent developments in the molecular characterization of Barrett's esophagus Dig Dis 16 1998 63 80 (Pubitemid 128530655)
9. American Gastroenterological Association American Gastroenterological Association Medical position statement on the management of barrett's esophagus Gastroenterology 140 2011 1084 1091
10. E.M. van Soest, J.P. Dieleman, and P.D. Siersema Increasing incidence of Barrett's oesophagus in the general population Gut 54 2005 1062 1066 (Pubitemid 41025895)
11. S.S. Devesa, W.J. Blot, and J.F. Fraumeni Jr Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 1998 2049 2053 (Pubitemid 28525384)
12. S. Mehta, I.T. Johnson, and M. Rhodes Systematic review: the chemoprevention of oesophageal adenocarcinoma Aliment Pharmacol Ther 22 2005 759 768 (Pubitemid 41564354)
13. D.M. Nguyen, P. Richardson, and H.B. El-Serag Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus Gastroenterology 138 2010 2260 2266
14. O.O. Ogunwobi, and I.L. Beales Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells Am J Gastroenterol 103 2008 825 837 (Pubitemid 351501115)
15. T.L. Vaughan, L.M. Dong, and P.L. Blount Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study Lancet Oncol 6 2005 945 952 (Pubitemid 41685227)
16. M. Hoffmeister, J. Chang-Claude, and H. Brenner Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study Int J Cancer 121 2007 1325 1330 (Pubitemid 47293801)
17. H. Xiao, and C.S. Yang Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention Int J Cancer 123 2008 983 990
18. R.E. Sampliner Practice Parameters Committee of the American College of Gastroenterology Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus Am J Gastroenterol 97 2002 1888 1895
19. D. Armstrong, J.R. Bennett, and A.L. Blum The endoscopic assessment of esophagitis: a progress report on observer agreement Gastroenterology 111 1996 85 92 (Pubitemid 26226887)
20. E. Montgomery, M.P. Bronner, and J.R. Goldblum Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation Hum Pathol 32 2001 368 378 (Pubitemid 32378298)
21. B.J. Reid, R.C. Haggitt, and C.E. Rubin Observer variation in the diagnosis of dysplasia in Barrett's esophagus Hum Pathol 19 1988 166 178 (Pubitemid 18091022)
22. M. Kerkhof, H. van Dekken, and E.W. Steyerberg Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists Histopathology 50 2007 920 927 (Pubitemid 46850080)
23. P. Tsibouris, M.T. Hendrickse, and P.E. Isaacs Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma Aliment Pharmacol Ther 20 2004 645 655 (Pubitemid 39279053)
24. D.M. Nguyen, H.B. El-Serag, and L. Henderson Medication usage and the risk of neoplasia in patients with Barrett's esophagus Clin Gastroenterol Hepatol 7 2009 1299 1304
25. L.A. Anderson, B.T. Johnston, and R.G. Watson Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia- adenocarcinoma sequence Cancer Res 66 2006 4975 4982
26. E.T. Hawk, and J.L. Viner Statins in esophageal cancer cell lines: promising lead? Am J Gastroenterol 103 2008 838 841 (Pubitemid 351501098)
27. P.C. Konturek, G. Burnat, and E.G. Hahn Inhibition of Barret's adenocarcinoma cell growth by simvastatin: involvement of COX-2 and apoptosis-related proteins J Physiol Pharmacol 58 Suppl 3 2007 141 148 (Pubitemid 47523111)